A5088411826- Ovarian cancer diagnosis and treatment
- Immune cells in cancer
- Reproductive System and Pregnancy
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Glycosylation and Glycoproteins Research
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Galectins and Cancer Biology
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
National Cancer Institute
2018-2023
National Institutes of Health
2023
Center for Cancer Research
2020-2023
Abstract Background NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended O-glycans expressed by its target cells. Here, we present outcomes phase I trial of in advanced solid tumors that have not responded standard treatments. Methods This was single site, open label 3 + dose escalation clinical trial. administered intravenously every two weeks 28-day cycle at level (DL) (1...
Ovarian cancer is the most lethal gynecologic and intrinsically resistant to checkpoint immunotherapies. We sought augment innate immunity, building on previous work with IFNs monocytes.Preclinical experiments were designed define mechanisms of cell death mediated by combination α γ monocytes. translated these preclinical findings into a phase I trial autologous IFN-activated monocytes administered intraperitoneally platinum-resistant or -refractory ovarian patients.IFN-treated induced...
6038 Background: Preclinical data suggest cell cycle checkpoint inhibition induces greater death in BRCA mutant HGSOC by causing replication stress and dysregulation of DNA damage responses. We hypothesized that prexasertib, a kinase 1 (CHK1) inhibitor, would be active mutated patients. Methods: conducted single center, two-stage phase II study prexasertib (105mg/m 2 IV every weeks) patients with known germline or somatic mutations. The primary endpoint was RECIST response rate (RR)....
e15002 Background: NEO-201 is a humanized IgG1 mAb that targets tumor-associated variants of CEACAM-5/6. NEO201 exerts anti-tumor activity by (NK)-mediated ADCC, CDC, and enhancing NK cell cytotoxicity through blockade CEACAM5-CEACAM1 interaction. The first in human phase I clinical trial ongoing. Neutropenia caused DLT was observed at 2mg/kg (DL 2). At DL2, 2/6 patients with colorectal cancers had stable disease. In the present study we evaluated correlation between response, status,...
<div>AbstractPurpose:<p>Ovarian cancer is the most lethal gynecologic and intrinsically resistant to checkpoint immunotherapies. We sought augment innate immunity, building on previous work with IFNs monocytes.</p>Patients Methods:<p>Preclinical experiments were designed define mechanisms of cell death mediated by combination α γ monocytes. translated these preclinical findings into a phase I trial autologous IFN-activated monocytes administered intraperitoneally...
<div>AbstractPurpose:<p>Ovarian cancer is the most lethal gynecologic and intrinsically resistant to checkpoint immunotherapies. We sought augment innate immunity, building on previous work with IFNs monocytes.</p>Patients Methods:<p>Preclinical experiments were designed define mechanisms of cell death mediated by combination α γ monocytes. translated these preclinical findings into a phase I trial autologous IFN-activated monocytes administered intraperitoneally...
<p>Supplementary Figure Legends</p>
<p>Supplementary figures and tables</p>
<p>Supplementary Figure Legends</p>
<p>Supplementary figures and tables</p>